NewKerala.com

Pharma PLI Schemes Surpass Targets with Rs 42K Cr Investment, Boosting Exports

India's Production-Linked Incentive schemes for pharmaceuticals have far surpassed investment targets, generating cumulative investments of nearly Rs 42,000 crore. The schemes have driven sales of over Rs 3.35 lakh crore, including substantial exports worth more than Rs 2.15 lakh crore. A key outcome is the domestic manufacturing of 726 Active Pharmaceutical Ingredients and related materials, with 191 being produced in India for the first time. The initiatives aim to boost manufacturing capabilities and reduce import dependency in the critical pharmaceutical sector.

Key Points: India's Pharma PLI Schemes Exceed Investment Targets

  • Investments hit Rs 41,943 cr vs Rs 17,275 cr target
  • Sales generated total Rs 3.35 lakh crore
  • Exports worth Rs 2.15 lakh crore achieved
  • 726 APIs/KSMs/DIs now manufactured in India
2 min read

India's pharmaceutical PLI schemes far exceed investment targets: Minister

India's pharmaceutical PLI schemes drive Rs 41,943 crore in investment, far exceeding targets, and generate over Rs 3.35 lakh crore in sales with significant exports.

"The investments substantially exceed the targeted committed investment of Rs 17,275 crore - Anupriya Patel"

New Delhi, March 20

India's production-linked incentive schemes for pharmaceuticals have driven cumulative investments of Rs 41,943 crore in both brownfield and greenfield projects, the Parliament was informed on Friday.

The investments substantially exceed the targeted committed investment of Rs 17,275 crore over the six-year period of the scheme, Minister of State for Chemicals and Fertilisers, Anupriya Patel, said in a written reply in the Lok Sabha.

The incentive scheme generated Rs 3,35,036 crore in sales from 1,988 products, the statement from Ministry of Chemicals and Fertilizers said.

The total sales figure includes exports worth Rs 2,15,248 crore, it said, adding that 726 Active Pharmaceutical Ingredients (APIs), Key Starting Materials (KSMs), and Drug Intermediates (DIs) are now being manufactured under the scheme, including 191 produced for the first time in the country.

Sale of these APIs or KSMs or DIs have resulted in cumulative domestic sales worth Rs 28,067 crore, which contributed to import reduction in the sector.

PLI scheme for Pharmaceuticals, approved in 2021, aims to boost India's manufacturing capabilities by increasing investment and production in the pharmaceuticals sector.

The scheme intends to incentivize production of high value medicines, complex generics and active pharmaceutical ingredients, while the PLI scheme for Bulk Drugs, approved in 2020, targets critical KSMs, DIs and APIs to reduce dependence on single sources.

Under the PLI scheme for Bulk Drugs, Rs 4,814 crore has been made in greenfield projects against a commitment of Rs 4,329.95 crore over six years, the statement further said.

Total capacity amounting to 91,077 metric tonnes per annum is committed for 33 products against the originally envisaged capacity of 82,270 metric tonnes per annum for 41 products identified under the scheme, it said.

Under this scheme, six new manufacturing units have been commissioned in Andhra Pradesh's Visakhapatnam, an aspirational district.

- IANS

Share this article:

Reader Comments

P
Priya S
Great to see the numbers, but I hope this translates to more affordable medicines for the common man. Sometimes these schemes boost exports and company profits, but the local prices don't come down. The focus should be on making healthcare accessible.
R
Rohit P
Manufacturing 191 products for the first time in India is the real achievement here. After the pandemic exposed our vulnerabilities, becoming self-reliant in critical drugs and ingredients is a strategic necessity. Jai Hind!
S
Sarah B
As someone working in the healthcare sector, I see this as a very positive step. The investment in Visakhapatnam, an aspirational district, is particularly good for regional development. Building capacity in tier-2 cities can create a more resilient supply chain.
V
Vikram M
The export figures are impressive – over 2 lakh crore! This proves that 'Make in India' can also mean 'Export from India'. Our pharma sector is truly a global champion. Hope the quality standards remain world-class.
M
Michael C
While the investment numbers are good, I have a respectful criticism. The article mentions "originally envisaged capacity for 41 products" but now it's for 33 products. We should also track if we are meeting the diversity of products planned, not just the total investment amount.
A
Ananya R

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50